Search research articles
Contact Us
Filters
Showing results (91-100 of 105) with videos related to
Page
of 11
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program
Hung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Scientific Reports
|
December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
Chung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
The Kaohsiung Journal of Medical Sciences
|
June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan
Szu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Hepatology International
|
March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
Te-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences
|
January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan
Szu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry
Tyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.
Infectious Diseases and Therapy
|
April 28, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan
Chun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, et al.
Hepatology International
|
January 21, 2024
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
Ming-Lung Yu, Chi-Ming Tai, Lein-Ray Mo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 3, 2021
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
Chi-Yi Chen, Chung-Feng Huang, Pin-Nan Cheng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
February 6, 2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan
Ching-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 105) with videos related to
Sort By:
Page
of 11
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program
Hung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Scientific Reports
|
December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
Chung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
The Kaohsiung Journal of Medical Sciences
|
June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan
Szu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Hepatology International
|
March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
Te-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences
|
January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan
Szu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry
Tyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.
Infectious Diseases and Therapy
|
April 28, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan
Chun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, et al.
Hepatology International
|
January 21, 2024
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
Ming-Lung Yu, Chi-Ming Tai, Lein-Ray Mo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 3, 2021
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
Chi-Yi Chen, Chung-Feng Huang, Pin-Nan Cheng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
February 6, 2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan
Ching-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, et al.
Page
of 11